DADC
AKBA icon

D.A. Davidson & Co’s Akebia Therapeutics AKBA Stock Holding History

D.A. Davidson & Co’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-480
Closed -$6K – 1099
2017
Q2 		$6K Hold
480
– – ﹤0.01% 2151
2017
Q1 		$4K Buy
+480
New +$4.69K ﹤0.01% 2196

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

D.A. Davidson & Co's AKBA Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Akebia Therapeutics (AKBA) in Q3 2017, closing a stake of 480 shares — an estimated $6K sold.

D.A. Davidson & Co first reported a position in AKBA in Q1 2017 and held it in 2 quarters. The position peaked at $6K in Q2 2017. 119 funds tracked by Wall St. Rank hold AKBA as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Akebia Therapeutics position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 480 Akebia Therapeutics shares in Q3 2017, an estimated $6K.
  • D.A. Davidson & Co first reported a position in Akebia Therapeutics in Q1 2017 and held it in 2 quarters.
  • D.A. Davidson & Co's Akebia Therapeutics position peaked at $6K in Q2 2017.
  • 119 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.